STOCK TITAN

Compass Therapeutics (CMPX) Stock Price, News & Analysis

CMPX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
52 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
-64.4% close of April 27, 2026
1-year change
-87.6% closing prices, November 18, 2025 to November 18, 2026
1-month change
-29% closing prices, October 16, 2026 to November 18, 2026

Company Description

Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth, with the goal of generating effective anti-tumor responses across a range of solid and hematologic malignancies. Compass Therapeutics was founded in 2014 and is headquartered in Boston, Massachusetts.

According to the company’s public disclosures, Compass has built a pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.

Core scientific focus and therapeutic approach

Compass Therapeutics describes its scientific strategy as centered on the interplay between angiogenesis (the formation of new blood vessels), immune regulation, and tumor biology. By targeting angiogenesis, the company aims to affect the tumor microvasculature, which can influence how tumors grow and respond to therapy. At the same time, its programs seek to activate effector cells in the tumor microenvironment and reduce immunosuppressive mechanisms that allow tumors to evade immune surveillance.

This multi-pathway approach is reflected in the company’s antibody-based product candidates, many of which are bispecific antibodies designed to engage more than one target. Publicly described programs include antibodies directed at DLL4 and VEGF-A, PD-1 and PD-L1, PD-1 and VEGF-A, and CD137. These targets are associated with angiogenesis, immune checkpoint regulation, and immune cell co-stimulation, which together are intended to support a coordinated anti-tumor immune response.

Key clinical and preclinical product candidates

Compass Therapeutics reports a pipeline that includes several named product candidates:

  • Tovecimig (DLL4 x VEGF-A bispecific antibody) – A bispecific antibody that targets DLL4 and VEGF-A. Tovecimig is being evaluated in the Phase 2/3 randomized COMPANION-002 study in patients with advanced biliary tract cancer (BTC). The company has stated that this study met its primary endpoint of overall response rate when tovecimig plus paclitaxel was compared with paclitaxel alone, and that analyses of key secondary endpoints, including progression-free survival (PFS) and overall survival (OS), are planned based on pre-specified events. Tovecimig has also been studied as monotherapy in patients with advanced, metastatic colorectal cancer (CRC) treated in later-line settings, where Compass has reported monotherapy activity and has highlighted outcomes in patients with DLL4-positive tumors.
  • CTX-8371 (PD-1 x PD-L1 bispecific antibody) – A bispecific antibody targeting PD-1 and PD-L1. In a Phase 1 dose-escalation study, Compass has reported responses in patients with both solid tumors and hematologic malignancies in the post-checkpoint inhibitor setting. Public updates describe deep and durable responses in indications such as non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC), as well as responses in Hodgkin Lymphoma (HL). The company has opened cohort expansions for CTX-8371 in TNBC and NSCLC and is evaluating potential accelerated pathways for HL in the post-checkpoint inhibitor setting.
  • CTX-10726 (PD-1 x VEGF-A bispecific antibody) – A bispecific, tetravalent antibody that simultaneously targets VEGF-A and PD-1. Compass reports that CTX-10726 is being developed for metastatic or locally advanced tumor types where checkpoint and angiogenesis signals are present. In preclinical studies described by the company, CTX-10726 demonstrated high-affinity binding to VEGF-A and PD-1, blocked VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose-dependent manner, and showed anti-tumor activity in multiple in vivo models. The company has indicated that CTX-10726 is undergoing IND-enabling studies and that it plans a Phase 1 dose-escalation study.
  • CTX-471 (CD137 agonist antibody) – A CD137 (4-1BB) agonist antibody that Compass states binds a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity. The company has indicated that it expects to initiate a Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56).

In addition to these named programs, earlier descriptions of the company’s pipeline reference candidates such as CTX-009 and a VEGF-IO bispecific, reflecting a broader effort to explore multiple antibody formats and targets within its core scientific framework.

Oncology focus and disease areas

Compass Therapeutics characterizes itself as an oncology-focused biopharmaceutical company. Across its clinical and preclinical programs, the company’s disclosures reference work in advanced biliary tract cancer, colorectal cancer, non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma, among other DLL4-positive and PD-(L)1-positive tumor types. The company’s public statements emphasize development in settings where patients often have limited approved therapeutic options, including later-line treatment of certain cancers and post-checkpoint inhibitor settings.

By designing antibodies that engage angiogenesis pathways and immune checkpoints simultaneously, or that provide immune co-stimulation, Compass aims to address tumors that may not respond adequately to single-pathway therapies. The company’s pipeline is described as being suitable for evaluation both as monotherapy and in combination with other agents, including standard-of-care regimens and other proprietary antibodies.

Capital markets and listing information

Compass Therapeutics, Inc. is listed on the Nasdaq Capital Market under the trading symbol CMPX. The company has filed shelf registration statements and conducted underwritten public offerings of common stock and pre-funded warrants, as described in its Form 8-K filings. In these filings, Compass has stated that it intends to use offering proceeds to fund research and clinical development of its product candidates, initial preparations for commercial readiness, and general corporate purposes. The company has also disclosed expectations regarding its cash and marketable securities and anticipated cash runway, while noting that these expectations are based on assumptions that may change.

Regulatory and reporting profile

As a U.S. public company, Compass Therapeutics files periodic and current reports with the Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q, and 8-K. Recent 8-K filings have covered financial results, corporate presentations, and material financing agreements. These filings provide additional detail on the company’s operating expenses, research and development activities, general and administrative costs, and balance sheet items such as cash, marketable securities, and lease obligations.

Position within biopharmaceutical development

Within the broader biopharmaceutical landscape, Compass Therapeutics presents itself as a company focused on antibody engineering and immuno-oncology. Its emphasis on bispecific antibodies targeting combinations such as DLL4/VEGF-A, PD-1/PD-L1, and PD-1/VEGF-A, alongside a CD137 agonist program, reflects a strategy of engaging multiple mechanisms relevant to tumor growth, angiogenesis, and immune modulation. Publicly available information highlights the company’s intention to use clinical and nonclinical data to guide the advancement of these candidates, including decisions about monotherapy versus combination approaches and selection of tumor types for further study.

Stock Performance

$0.6232
+2.00%
+0.0122
After hoursChange vs the $0.6110 closeLast updated: at
-87.6%
Performance 1 year
$111.4M

Compass Therapeutics (CMPX) closed at $0.6110 on November 18, 2026. Over the past 12 months, the price has lost 87.6%.

See what a $1,000 investment in CMPX would be worth today

Average down calculator for CMPX

CMPX Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Compass Therapeutics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, clinical trial. View all CMPX news →

Insider Radar

Net Buyers
90-Day Summary
32,500
Shares Bought
0
Shares Sold
3
Transactions
Most Recent Transaction
Lerner Neil (Chief Accounting Officer) bought 10,000 shares @ $0.5900 on November 17, 2026

Insider buying activity at Compass Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Compass Therapeutics reported operating income of -$72.8M in FY2025, and net income was -$66.5M. The company generated -$49.1M in operating cash flow. The current ratio was 15.02, measuring current assets divided by current liabilities.

$0
Revenue (FY2025)
-$66.5M
Net Income (FY2025)
-$49.1M
Operating Cash Flow

Upcoming Events

JAN
05
January 5, 2027 Corporate

25% option vesting cliff

First vesting: 25% of each grant vests after one year (cliff).
JAN
05
January 5, 2027 - January 5, 2030 Corporate

Monthly option vesting period

Remaining 75% vests in 36 monthly installments following the one-year cliff.
H2
2027
H2 2027 Clinical

CTX-471 Phase 2 data

Compass expects initial CTX-471 Phase 2 data in the second half of 2027 (Jul–Dec 2027); timing, venue, and data details TBA.
OCT
13
October 13, 2027 Corporate

Option first vesting

25% of a 200,000-share inducement option grant vests on the first anniversary; exercise price $0.86, under 2025 Inducement Plan.
OCT
13
October 13, 2030 Corporate

Option full vesting

Remaining 75% of the 200,000-share option vests over 36 monthly installments, completing four-year vesting schedule.
JAN
05
January 5, 2036 Corporate

Option expiration (10-year)

Options expire 10 years after grant; final exercise deadline per grants.
OCT
13
October 13, 2036 Corporate

Option expiration

10-year term expiration of the 200,000-share inducement stock options granted under the 2025 Inducement Plan.

Compass Therapeutics has 7 upcoming scheduled events. The next event, "25% option vesting cliff", is scheduled for January 5, 2027 (in 48 days). Investors can track these dates to stay informed about potential catalysts that may affect the CMPX stock price.

Short Interest History

Last 12 Months

Short interest in Compass Therapeutics (CMPX) currently stands at 40.8 million shares, down 2.5% from the previous reporting period, representing 28.6% of the float. Since November 2025, short interest has increased by 134.2%.

Days to Cover History

Last 12 Months

Days to cover for Compass Therapeutics (CMPX) currently stands at 18.9 days, up 239.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 128.1%. Across the settlements charted above, it has ranged from 1.4 to 18.9 days.

CMPX Company Profile & Sector Positioning

Compass Therapeutics (CMPX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing CMPX often look at related companies in the same sector, including ALX Oncology Holdings Inc. (ALXO), NeOnc Technologies Holdings, Inc. (NTHI), MacroGenics, Inc. (MGNX), BridgeBio Oncology Therapeutics, Inc. (BBOT), and Armata Pharmaceuticals, Inc. (ARMP). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CMPX's relative position within its industry.

Frequently Asked Questions

The current stock price of Compass Therapeutics (CMPX) is $0.6232 in after-hours trading as of November 18, 2026.

The market cap of Compass Therapeutics (CMPX) is approximately $111.4M. Learn more about what market capitalization means .

The FY2025 revenue of Compass Therapeutics (CMPX) is $0, from its most recent completed fiscal year.

The FY2025 net income of Compass Therapeutics (CMPX) is -$66.5M, from its most recent completed fiscal year.

The operating cash flow of Compass Therapeutics (CMPX) is -$49.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Compass Therapeutics (CMPX), current assets divided by current liabilities, was 15.02 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Compass Therapeutics (CMPX) is -$72.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Its work centers on the relationship between angiogenesis, the immune system, and tumor growth.

Compass focuses on how angiogenesis, immune regulation, and tumor growth interact. The company designs antibody-based therapeutics to modulate the tumor microvasculature, activate effector immune cells, and alleviate immunosuppressive mechanisms that tumors use to evade immune surveillance.

Public disclosures describe several product candidates, including tovecimig (a DLL4 x VEGF-A bispecific antibody), CTX-8371 (a PD-1 x PD-L1 bispecific antibody), CTX-10726 (a PD-1 x VEGF-A bispecific tetravalent antibody), and CTX-471 (a CD137 agonist antibody). Earlier descriptions also reference CTX-009 and a VEGF-IO bispecific.

Compass reports clinical and planned activity in oncology indications such as advanced biliary tract cancer, colorectal cancer, non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma, along with other DLL4-positive and PD-(L)1-positive tumor types.

Tovecimig is a DLL4 x VEGF-A bispecific antibody. It is being evaluated in the COMPANION-002 Phase 2/3 randomized study in patients with advanced biliary tract cancer, where tovecimig plus paclitaxel has been reported to improve overall response rate versus paclitaxel alone. It has also been studied as monotherapy in advanced, metastatic colorectal cancer in later-line settings.

For CTX-8371, a PD-1 x PD-L1 bispecific antibody, Compass has reported responses in a Phase 1 dose-escalation study in patients with solid tumors and hematologic malignancies in the post-checkpoint inhibitor setting. Deep and durable responses have been described in non-small cell lung cancer and triple negative breast cancer, and responses have been reported in Hodgkin Lymphoma.

CTX-10726 is a bispecific, tetravalent antibody targeting VEGF-A and PD-1. Compass states that preclinical studies showed high-affinity binding to both targets, blockade of VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose-dependent manner, and anti-tumor activity in multiple in vivo models. It is in IND-enabling studies with plans for a Phase 1 trial.

CTX-471 is a CD137 agonist antibody that Compass reports binds a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity. The company has indicated that it expects to initiate a Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56).

Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts, according to the company’s press releases and SEC filings.

Compass Therapeutics, Inc.’s common stock trades on the Nasdaq Capital Market under the ticker symbol CMPX. SEC filings list the security as common stock with a par value per share.